Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIPOD intraperitoneal and intravenous chemotherapy for ovarian cancer
ACTRN12606000502538Phase 2Completed
- Sponsor
- Australia New Zealand Gynaecological Oncology Group
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel and cisplatin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Australia New Zealand Gynaecological Oncology Group. Primary endpoint: Feasibility of treatment delivery. Started Sep 2007; status: completed.
02
Drugs
paclitaxelcisplatin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on ACTRN12606000502538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000502538.